Josef Sýkora

Prof. Dr. Josef Sýkora

Charles University Faculty of Medicine in Pilsen, Pilsen, Czech Republic
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2005 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
Josef SýkoraJosef Sýkora
Josef Sýkora
KVKristýna Valecková
Kristýna Valecková
JAJana Amlerová
Jana Amlerová
KSKonrad Siala
Konrad Siala
PDPetr Dedek
Petr Dedek
JSJan Schwarz
Jan Schwarz
To determine the efficacy of triple therapy supplemented with a specially designed fermented milk product containing specific probiotic Lactobacillus casei (L. casei) DN-114 001 strain on Helicobacter pylori eradication in children. Lactobacillus species possess in vitro activity against H. pylori. There are no consistent data on the impact of eradication therapy supplemented with probiotics on H. pylori cure rates in childhood in vivo. Multicenter, prospective, randomized, double-blind controlled study. Eighty-six symptomatic H. pylori-positive children were randomized either to receive the control treatment of omeprazole, amoxicillin, and clarithromycin (OAC) for 7 days or the test treatment of omeprazole, amoxicillin, and clarithromycin for 7 days supplemented with fermented milk (Actimel) containing L. casei DN-114 001 (OAC-LC), for 14 days. H. pylori status was assessed at 4 weeks following therapy using two noninvasive tests. Intention-to-treat (ITT) based eradication rates for the OAC-LC group were 84.6% (95% CI, 71.2%-95.5%), and 91.6% (95% CI, 76.9%-98.2%) by per-protocol (PP) analysis. Eradication in the OAC group was 57.5% (95% CI, 42.2%-72.3%) in the ITT set and 61.3% (95% CI, 44.4%-75.0%) in the PP group. Eradication success was higher in the OAC-LC group compared with the OAC group in both ITT (P=0.0045) and PP analysis (P=0.0019). Primary resistance for clarithromycin could be determined in 21.2%. Side effects were infrequent. Drug compliance was good throughout the study. Supplementation with fermented milk, containing live special probiotic L. casei DN-114 001, confers an enhanced therapeutic benefit on H. pylori eradication in children with gastritis on triple therapy.

6 December 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
MVMarek Vebr
Marek Vebr
RPRenáta Pomahačová
Renáta Pomahačová
Josef SýkoraJosef Sýkora
Josef Sýkora
JSJan Schwarz
Jan Schwarz
Inflammatory bowel disease (IBD) is a lifelong inflammatory immune mediated disorder, encompassing Crohn’s disease (CD) and ulcerative colitis (UC); however, the cause and specific pathogenesis of IBD is yet incompletely understood. Multiple cytokines produced by different immune cell types results in complex functional networks that constitute a highly regulated messaging network of signaling pathways. Applying biological mechanisms underlying IBD at the single omic level, technologies and genetic engineering enable the quantification of the pattern of released cytokines and new insights into the cytokine landscape of IBD. We focus on the existing literature dealing with the biology of pro- or anti-inflammatory cytokines and interactions that facilitate cell-based modulation of the immune system for IBD inflammation. We summarize the main roles of substantial cytokines in IBD related to homeostatic tissue functions and the remodeling of cytokine networks in IBD, which may be specifically valuable for successful cytokine-targeted therapies via marketed products. Cytokines and their receptors are validated targets for multiple therapeutic areas, we review the current strategies for therapeutic intervention and developing cytokine-targeted therapies. New biologics have shown efficacy in the last few decades for the management of IBD; unfortunately, many patients are nonresponsive or develop therapy resistance over time, creating a need for novel therapeutics. Thus, the treatment options for IBD beyond the immune-modifying anti-TNF agents or combination therapies are expanding rapidly. Further studies are needed to fully understand the immune response, networks of cytokines, and the direct pathogenetic relevance regarding individually tailored, safe and efficient targeted-biotherapeutics.

17 August 2010 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
Josef SýkoraJosef Sýkora
Josef Sýkora
KSKonrad Siala
Konrad Siala
MHMichal Huml
Michal Huml
JVJana Varvařovská
Jana Varvařovská
JSJan Schwarz
Jan Schwarz
RERenáta
Renáta

23 July 2009 in Helicobacter
Verified
Journal Article
Closed access
PDF file
Josef SýkoraJosef Sýkora
Josef Sýkora
KSKonrad Siala
Konrad Siala
JVJana Varvařovská
Jana Varvařovská
FPFN Plzeň
FN Plzeň
RPRenáta Pomahačová
Renáta Pomahačová
MHMichal Huml
Michal Huml

1 May 2006 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
Josef SýkoraJosef Sýkora
Josef Sýkora
IŠIvan Šubrt
Ivan Šubrt
PDPetr Dìdek
Petr Dìdek
KSKonrad Siala
Konrad Siala
JSJan Schwarz
Jan Schwarz
FSFrantišek Stožický
František Stožický

1 September 2004 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
Josef SýkoraJosef Sýkora
Josef Sýkora
AMAlexander Malán
Alexander Malán
JZJan Záhlava
Jan Záhlava
JVJana Varvars̆ká
Jana Varvars̆ká
FSFrantišek Stozĭcký
František Stozĭcký
JSJan Schwarz
Jan Schwarz